Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Non-cash Items (2016 - 2018)

Historic Non-cash Items for Amicus Therapeutics (FOLD) over the last 9 years, with Q1 2018 value amounting to $40.6 million.

  • Amicus Therapeutics' Non-cash Items rose 913.98% to $40.6 million in Q1 2018 from the same period last year, while for Mar 2018 it was $40.6 million, marking a year-over-year increase of 913.98%. This contributed to the annual value of $8.0 million for FY2017, which is 7630.39% down from last year.
  • Latest data reveals that Amicus Therapeutics reported Non-cash Items of $40.6 million as of Q1 2018, which was up 913.98% from $8.0 million recorded in Q4 2017.
  • Amicus Therapeutics' 5-year Non-cash Items high stood at $40.6 million for Q1 2018, and its period low was $5.3 million during Q3 2015.
  • Moreover, its 5-year median value for Non-cash Items was $11.2 million (2015), whereas its average is $18.8 million.
  • Over the last 5 years, Amicus Therapeutics' Non-cash Items had its largest YoY gain of 33811.02% in 2017, and its largest YoY loss of 7630.39% in 2017.
  • Amicus Therapeutics' Non-cash Items (Quarter) stood at $7.7 million in 2014, then crashed by 31.13% to $5.3 million in 2015, then surged by 535.51% to $33.7 million in 2016, then plummeted by 76.3% to $8.0 million in 2017, then surged by 408.42% to $40.6 million in 2018.
  • Its Non-cash Items was $40.6 million in Q1 2018, compared to $8.0 million in Q4 2017 and $32.4 million in Q3 2017.